Results 61 to 70 of about 87,925 (315)
European Journal of Haematology, Volume 110, Issue 1, Page 67-76, January 2023., 2023 Abstract Background The SARS‐COV‐2 (Covid‐19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid‐19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality.
Irene Graf +7 more
wiley +1 more source
Multidisciplinary Respiratory Medicine, 2012 Background Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor.
Nakashima Shota +10 more
doaj +1 more source
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
New England Journal of Medicine, 2010 BACKGROUND Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...
G. Saglio +15 more
semanticscholar +1 more source
Japanese Journal of Clinical Immunology, 2009 The progress in molecular targeting therapy includes two tides, namely, small molecule compounds and large molecule biological agents. Although the latter prevails in the field of clinical immunology, the former attracts more and more attention in these few years.
openaire +3 more sources
Reintroduction of Imatinib in GIST [PDF]
Journal of Gastrointestinal Cancer, 2013 Abstract Purpose This review examines the clinical evidence showing that imatinib can be prescribed to treat recurrence or progression of gastrointestinal stromal tumors (GIST) in patients who interrupted first-line imatinib therapy in the adjuvant or advanced/metastatic setting ...
openaire +3 more sources
A critical review of bioactive glasses and glass–ceramics in cancer therapy
International Journal of Applied Glass Science, Volume 14, Issue 1, Page 69-87, January 2023., 2023 Abstract There is an ongoing profound shift in using glass as a primarily passive material to one that instills active properties. We believe and demonstrate that bioactive glasses (BGs) and glass–ceramics (BGCs) as functional biomaterials for cancer therapy can transform the world of healthcare in the 21st century.
Ali Moeini +5 more
wiley +1 more source
BMC Cancer, 2010 Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available.
Weigel Marion T +10 more
doaj +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan ...
arxiv +1 more source
British Journal of Cancer, 2019 Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations.
C. Serrano +18 more
semanticscholar +1 more source
Haematologica, 2019 Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep molecular ...
Christian Michel +60 more
doaj +1 more source